These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10214683)

  • 1. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study.
    McCormack J; Greenhalgh T
    BMJ; 2000 Jun; 320(7251):1720-3. PubMed ID: 10864554
    [No Abstract]   [Full Text] [Related]  

  • 2. New Insights Into the Genetics of Glycemic Response to Metformin.
    Pearson ER
    Diabetes Care; 2024 Feb; 47(2):193-195. PubMed ID: 38241501
    [No Abstract]   [Full Text] [Related]  

  • 3. Should Metformin Continue as First-Line Pharmacotherapy for Patients With Type 2 Diabetes? No: Other Drugs Have Stronger Evidence of Benefit.
    Barry HC; Shaughnessy AF
    Am Fam Physician; 2024 Mar; 109(3):202-203. PubMed ID: 38574205
    [No Abstract]   [Full Text] [Related]  

  • 4. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors.
    Onitilo AA; Engel JM; Glurich I; Stankowski RV; Williams GM; Doi SA
    Cancer Causes Control; 2012 Jul; 23(7):991-1008. PubMed ID: 22527174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin protects against dementia in diabetes.
    Fyfe I
    Nat Rev Neurol; 2023 Dec; 19(12):711. PubMed ID: 37940646
    [No Abstract]   [Full Text] [Related]  

  • 6. AI-supported insulin dosing for type 2 diabetes.
    Davis GM; Shao H; Pasquel FJ
    Nat Med; 2023 Oct; 29(10):2414-2415. PubMed ID: 37821684
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin as an early treatment for type 2 diabetes: ORIGIN or end of an old question?
    Del Prato S; Bianchi C; Dardano A; Miccoli R
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S198-204. PubMed ID: 23882046
    [No Abstract]   [Full Text] [Related]  

  • 8. Fasting, Meal Substitute Improved Blood Sugar More Than Diabetes Drugs.
    Harris E
    JAMA; 2024 Aug; 332(5):362-363. PubMed ID: 38995658
    [No Abstract]   [Full Text] [Related]  

  • 9. The daunting task of recruiting insulin-treated patients living with type 2 diabetes mellitus for intensive lifestyle interventions.
    Sun CJ; Nguyen É; Prentki M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2024 Aug; 26(8):3486-3488. PubMed ID: 38840460
    [No Abstract]   [Full Text] [Related]  

  • 10. Age- and sex-specific profiles of temporal fasting plasma glucose variability in a population undergoing routine health screening.
    Lartey AH; Li X; Li Z; Zhang Q; Wang J
    BMC Public Health; 2021 Feb; 21(1):320. PubMed ID: 33563261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin monotherapy vs. combination therapy.
    Ebell MH
    Am Fam Physician; 2005 Mar; 71(5):899. PubMed ID: 15768618
    [No Abstract]   [Full Text] [Related]  

  • 14. [Impact of intensive blood glucose control with hypoglycemic sulfamides, metformin or insulin on complications of non-insulin dependent diabetes].
    André P
    Rev Epidemiol Sante Publique; 1999 Mar; 47(1):93-5. PubMed ID: 10214683
    [No Abstract]   [Full Text] [Related]  

  • 15. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin: response to Barnett et al.
    Kanna B; Abreu-Pacheco H
    Diabetes Care; 2007 Feb; 30(2):445-6; author reply 446. PubMed ID: 17259531
    [No Abstract]   [Full Text] [Related]  

  • 16. Follow-up of intensive glucose control in type 2 diabetes.
    Lund SS; Rossing P; Vaag AA
    N Engl J Med; 2009 Jan; 360(4):416; author reply 418. PubMed ID: 19164195
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.